Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Integrins

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Integrins. Displaying page 1 of 1.
    EudraCT Number: 2021-006881-19 Sponsor Protocol Number: TV48574-IMM-20036 Start Date*: 2022-12-21
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerat...
    Medical condition: Moderate to severe Ulcerative colitis or moderate to severe Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.0 100000004856 10011400 Crohn's colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) PL (Ongoing) AT (Ongoing) DE (Trial now transitioned) IT (Ongoing) CZ (Trial now transitioned) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002130-18 Sponsor Protocol Number: C1034T02 Start Date*: 2007-02-19
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 1/2 , Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human av Integrins (CNTO 95), Alone and in Combination with Dacarbaz...
    Medical condition: Malignant Melanoma Stage IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000659-11 Sponsor Protocol Number: GLPG3970-CL-210 Start Date*: 2020-09-10
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005766-39 Sponsor Protocol Number: C1034T08 Start Date*: 2007-04-03
    Sponsor Name:Centocor B.V.
    Full Title: A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Su...
    Medical condition: Hormone refractory prostate cancer (HRPC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) NL (Completed) AT (Prematurely Ended) DE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006260-52 Sponsor Protocol Number: THV01-11-01 Start Date*: 2012-10-12
    Sponsor Name:THERAVECTYS
    Full Title: A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or ...
    Medical condition: Human Immunodeficiency Virus type 1 infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005538-20 Sponsor Protocol Number: BA2011/15/02 Start Date*: 2012-05-15
    Sponsor Name:BioAlliance Pharma
    Full Title: SAFETY AND EFFICACY OF INTRAMUSCULAR ELECTROTRANSFER OF PLASMID AMEP IN PATIENTS SUFFERING FROM ADVANCED OR METASTATIC MELANOMA: AN OPEN-LABEL PHASE I/II CLINICAL TRIAL THE AIMM STUDY (AMEP IN MET...
    Medical condition: Treatment of patients suffering from advanced or metastatic melanoma (stages III, IV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016870-33 Sponsor Protocol Number: CILENT-0902 Start Date*: 2010-05-20
    Sponsor Name:Centre Oscar Lambret
    Full Title: Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study
    Medical condition: Newly diagnosed diffuse intrinsic pontine glioma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006143 Brain stem glioma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004849-18 Sponsor Protocol Number: EMD121974-010 Start Date*: 2005-07-18
    Sponsor Name:Merck KGaA
    Full Title: Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – ...
    Medical condition: Newly diagnosed Glioblastoma (Astrocytoma, WHO grade IV)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10018336 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006644-19 Sponsor Protocol Number: CRISTAL Start Date*: 2009-01-29
    Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA
    Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004217-26 Sponsor Protocol Number: CSUC-01/16 Start Date*: 2017-04-21
    Sponsor Name:InDex Pharmaceuticals AB
    Full Title: A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients
    Medical condition: Moderate to Severe left-sided Active Ulcerative Colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SE (Completed) ES (Completed) CZ (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004652-11 Sponsor Protocol Number: MA41419 Start Date*: 2020-08-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: RANDOMIZED, OPEN-LABEL PHASE 3B STUDY OF ETROLIZUMAB BASED INDUCTION THERAPY COMBINATIONS FOLLOWED BY ETROLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Medical condition: Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 17:50:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA